Abstract
Heritability studies on sport-related traits accepted that endurance, speed, power, and strength abilities include an active genetic predisposition to elite soccer participation. This study evaluates the influence of selected genetic variants on performance in speed, power, and strength laboratory tests on a group of elite soccer players, including their playing position. A ninety-nine male elite soccer players were compared to controls (n = 107) and tested for quadriceps and hamstrings isokinetic strength at speed 60°/s, 180°/s, and 300°/s, jump performance, and genotypes of ACTN3 (R577X, rs1815739), ACE (I/D, rs1799752), NOS3 (Glu298Asp, rs1799983), AMPD1 (34C/T, rs17602729), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761) and IL1RN (VNTR 86-bp). The ACTN3 XX homozygotes in defenders had lower quadriceps and hamstring isokinetic strength in all tested speeds than ACTN3 RX and RR genotypes (p < 0.05). The ACTN3 RR homozygotes in defenders had higher quadriceps strength in all tested velocities than the RX heterozygotes (p < 0.05). We also found other associations between playing-position in soccer and increased strength of lower limbs for AMPD1 CC and NOS3 Glu/Glu genotypes, and IL1RN*2 allele carriers. Total genetic score regression explained 26% of the variance in jump performance and isokinetic strength. The ACTN3 R allele, NOS3 Glu/Glu genotypes, and IL1RN*2 allele pre-disposed the attackers and defenders playing position in elite soccer, where those positions have higher strength and power measures than midfielders. Midfielders have lower strength and power conditions than other playing positions without relation to strength and power genes.
Keywords: Football, Isokinetic, Jump, Muscle strength, Sport genomic, Performance
INTRODUCTION
Elite soccer is highly competitive, and only a minority of players can participate in the world’s best soccer leagues. This fact also relates to the high complexity of soccer requirements, including technical, tactical, psychological, and physiological domains. The main physiological factors are the combination of endurance and speed [1–4], like repeated short sprints [5, 6]; moreover, current soccer increases strength and power requirements. Based on estimations of heritability studies on sport-related traits, it is generally accepted that endurance, speed-power, and strength abilities include a genetic determination [7–10], which might be explained at least partly through the genetics of muscle fibers specificity [11, 12].
Among various physical constraints for soccer players, the knee extensors and flexors’ concentric and eccentric strength correlate with soccer sprints [13–15] and deceleration ability [16] and differs by soccer-playing positions [17, 18]. Therefore, the knee flexors and extensors’ force at different speeds can generally explain the necessary force-velocity predisposition of elite players [19], which are possible predictors of soccer players’ agility and jump performance [20, 21]. Concerning the force-velocity profile, the soccer performance is specific by high speed running and sprinting [1, 22], acceleration and deceleration [23], isokinetic strength [18], and vertical jump performance [24, 25]. Since there is a clear cue between playing position and conditioning specificity, it is still unknown whether the force-velocity specificity might be genetically determined for playing position in the elite soccer level. On the other hand, some genetic markers have been associated with soccer attackers’ metabolic traits [26].
Many candidate gene studies have investigated the influence of several genetic polymorphisms on athletes’ speed, power, and strength performance during the past few years [7, 27]. In those studies, positive associations of “speed, power, and strength” genotypes have been found in groups of soccer players for the ACTN3 gene [28–32] or the PPARA gene [32–34]. Recently, the metanalyses of Weyerstrass et al. (2018) identified nine genetic polymorphisms for power phenotype: ACE (rs4363, rs1799752), ACTN3 (rs1815739), AGT (rs699), IL6-174 (rs1800795), MnSOD (rs1799725), NOS3 (rs1799983, rs2070744) and SOD2 (rs4880) [35], whereas some of them overlap with findings of current review from 2020 [36].
Since there are known genetic determinants for soccer conditioning, there is a lack in understanding genetic determinants for elite soccer level and playing position. Therefore, this study evaluates the influence of genetic variants on performance in speed, power, and strength laboratory tests on a group of elite soccer players concerning their playing position (attacker, defender, midfielder, and goalkeeper). We target the seven gene polymorphisms previously associated with speed, power, and strength ACTN3 (R577X, rs1815739), ACE (I/D, rs1799752), NOS3 (Glu298Asp, rs1799983), AMPD1 (34C/T, rs17602729), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761) and IL1RN (VNTR 86-bp).
MATERIALS AND METHODS
We performed a cross-sectional study with genotyping, vertical jumps, and isokinetic measurement of knee flexion and extension at three different angular speeds. Before the measurement, there was no training session or other demanding physical activity. The genotype samples were gathered before the participant general warm-up, which included 5 to 10 minutes of aerobic exercise on a treadmill/bike ergometer up to 140 beats per minute, followed by 5 to 10 minutes of individual static stretching, and 5 to 10 minutes of dynamic stretching presented by hops and dynamic lunges. After the warming-up, all players underwent vertical jump testing, followed by testing on an isokinetic dynamometer with 3 minutes rest interval between individual attempts.
Subjects
A ninety-nine Caucasian male soccer players (25.4 ± 4.51 y, 181.4 ± 6.11 cm, 77.4 ± 7.22 kg, Supplementary material Table S1) were recruited from five professional Czech soccer teams participating in the first (88 soccer players) and second national (11 soccer players) soccer league. Fifteen players reached the level of playing in the national team. For later frequency comparison of genotypes and alleles, we used 107 Czech healthy controls (from age 18 to 65) from whole-genome sequencing Czech national project Enigma, CZ.01.1.02/0.0/0.0/16_084/0010360. We calculated most represent allele frequency from targeted gene sites, which were used as a reference in our study. We could not analyze some of the hotspots due to the sequencing kit’s limitations, uncovered regions, and low mapping quality. Some of the genes cannot be studied due to the repetitive areas, which cause a wildly inaccurate variant calling process. All subjects signed informed consent at the beginning of the study participation, approved by the Ethics Committee of Faculty of Physical Education, Charles University (No. 145/2016, issued on October 21, 2016).
Vertical jump testing
The measurement was performed using the force plates (Kistler 8611, Switzerland) with a sampling frequency of 1000 Hz for three types of standardized vertical jumps, countermovement jump with the support of upper limbs swing, countermovement jump without hands on the waist, and a squat jump. Each jump test was repeated three to five times based on the subject’s choice, with at least 10 seconds between each jump and the jump type. The data were processed by BioWare software (Kistler Holding AG, Winterthur, Switzerland) and further calculation of the maximum height of the jump, the maximum force, the maximum force per kg of bodyweight [N/kg], and the achieved impulse of force per kg of the subject’s body weight [N·s/kg].
Isokinetic strength
Knee extensors and flexors strength was measured at three different angular velocities of 60°/s, 180°/s, and 300°/s using isokinetic dynamometer Cybex Human Norm (Cybex Norm®, Humac, CA, USA) and manufactural software (HUMAC2015®, version 15.000.0044). Subjects performed two repetitions for each angular velocity with 30 s rest between the velocities. During the testing, subjects were verbally encouraged and had full visual contact with the screen showing the current performance level. The extracted data included peak force [Nm] and peak force per kg [Nm/kg] at the concentric phases.
Genotyping
Molecular genetic analysis was performed in the Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague. We performed genotyping with DNA samples obtained from epithelial mouth cells collected by a trained individual by cheek brushes (microRheologics, Italy) against the inside of each subject’s cheek for approximately 15 s. Subjects were asked not to consume any food or drink in the 30 minutes before sample collection [37]. Cheek brushes were air-dried for at least 8 hours and later stored at -80°C until the DNA extraction, which was performed for a maximum of 2 weeks after the collection. The head of every cheek brush was cut and insert into a screw 2 ml cap tube before the extraction. The head of every cheek brush was cut and insert into a screw 2 ml cap tube before the extraction. DNA was extracted using the isolation kit QIAamp DNA Mini Kit (QIAgen, Germany) according to the manufacture’s instructions, with minor adjustments. Extracted samples were stored at -80°C. The DNA samples were quantified using a Polymerase chain reaction method (PCR) based on previous studies [38, 39]; the procedure details are in Supplementary material Tables S2 and S3. The gradient thermocycler Labcycler (SensoQuest, Germany) was used for PCR reaction. The digested product was visualized by 3% agarose gel electrophoresis in the horizontal electrophoresis device HU10 (SCIE-PLA, England) and identified by ethidium bromide staining [40]. Software visualization was performed by the UV light device G: BOX Chemi HR16 (Syngene, England).
The combined influence of the studied polymorphisms
The combined influence of the studied polymorphisms for each soccer player was done using the total genetic score (TGS) by Williams and Folland algorithm [41], where the raw score was transformed to a scale of 0–100: TGS = (100/14) × (GSACE + GSACTN3 + GSBDKRB2 + GSNOS3+ GSAMPD1 + GSUCP2 + GSIL1RN). In this calculation, 14 results from multiplying 7 (the number of studied polymorphisms) by 2 (the score is given to the optimal explosive-leg-strength genotype, where the score given to the optimal strength and power genotype is described in Table 1. The TGS was also calculated for genotypes with phenotype significant results TGSsig, where TGSsig = (100/2 × n) × (GS 1st gene + GS 2nd gene + GS n gene). In this calculation n is the number of genes.
TABLE 1.
Total genetic score counts for each examined genotype.
| Genotype | Total genetic score count |
|---|---|
| ACE (I/D) | 0 = II, 1 = ID, 2 = DD |
| ACTN3 (R577X) | 0 = XX, 1 = RX, 2 = RR |
| BDKRB2 (9/+9) | 0 = +9 + 9, 1 = +9 – 9, 2 = –9 – 9 |
| NOS3 (Glu298Asp) | 0 = Asp/Asp, 1 = Glu/Asp, 2 = Glu/Glu |
| AMPD1 (Gln12X) | 0 = TT, 1 = CT, 2 = CC |
| UCP2 (Ala55Val) | 0 = CC, 1 = CT, 2 = TT |
| IL1RN (VNTR 86-bp) | 0 = 1/1 or 1/3, 1 = 1/2 or 2/3, 2 = 2/ 2 |
Statistical Analyses
NCSS statistical software (NCSS, USA) was used to calculate HardyWeinberg equilibrium and chi-square analysis for testing the allele frequencies determined by gene counting. We used Chi-square analysis to compare genotype distribution, allele frequencies between the group of soccer players and healthy, and frequencies concerning the playing position inside the soccer players group, where p values of < 0.05 were considered statistically significant. The regression analyses, correlation, and group comparison have been performed in STATISTICA software (13.5. TIBCO software, Palo Alto, CA, USA), with a statistical significance level set up for 0.05. The Kolmogorov Smirnov test has calculated the data normality.
One way ANOVA was used to compare performance differences by genotype groups of soccer players (isokinetic/jump performance × genotype), and the two way ANOVA has been used to compare performance differences between genotypes in each playing position (isokinetic/jump performance × genotype × playing position) considering effect size by partial eta square (µ2) and differences by Unequal HSD post hoc test. µ2 was considered 0.02–0.12, 0.13–0.25, and > 0.26 as weak, moderate, and strong associations, respectively [42]. The two way ANOVA has been performed only in the sub-groups with n above 6.
A Spearman correlation coefficient and multiple linear regression model with a step-down (backward) procedure were used to explore the predictive role of the TGS variable with correlated muscle-strength and jump performance phenotypes. The TGS was calculated for all analyzed genotypes and for genotypes with phenotype significant results – TGSsig.
RESULTS
Physiological studies
The data from subgroups did not show disruption of normality. One way ANOVA showed differences in m. quadriceps strength among positions at 60°/s (F3, 181 = 7.3, p < 0.001, µ2 = 0.08), 180°/s (F3, 181 = 6.7, p < 0.001, µ2 = 0.04) and 300°/s (F3, 170 = 8.6, p < 0.001, µ2 = 0.10) in whole group, where midfield players resulted in lower quadriceps strength than other playing positions (Figure 1). The hamstring strength resulted in difference at 60°/s (F3, 181 = 6,4, p < 0.001, µ2 = 0.04), 180°/s (F3, 181 = 5.9, p = 0.0081 µ2 = 0.06) and 300°/s (F3, 170 = 6.5, p < 0.001, µ2 = 0.07) in whole group, where midfield players resulted in lower hamstring strength than other playing positions (Supplementary material Figure S1).
FIG. 1.
Quadriceps and hamstring strength for ACTN3 R577X genotypes and speeds of contraction in soccer player positions.
†Significantly higher than other genotype groups at defined playing position and speed of contraction. †† significantly higher than other genotypes groups at all speeds of contraction regardless of playing-position. *Significantly lower than other genotype groups at defined playing position and speed of contraction. ** Significantly lower than other genotypes groups at all speeds of contraction regardless of playing position. ‡ Significantly lower than other genotype groups in midfielders at 300° speed of contraction. Significance is according to ANOVA and HSD test.
Case-control genetic studies
All genotype data did not disrupt the Hardy-Weinberg equilibrium, and only NOS3 Glu298Asp differ in the allelic frequency in defenders, where defenders have higher Glu allele frequency than controls (Table 2). The ACE ID, BDKRB2 +9/-9, and IL1RN VNTR polymorphisms did not have reference values in our control group because genotyping was not available in these polymorphisms; therefore, this comparison was not possible (Table 2). We identified no subjects in the following subgroups: ACTN XX in attackers, NOS3 Asp/Asp in attackers and goalkeepers, AMPD1 TT in all subjects, and IL1RN*2/ IL1RN*2 in goalkeepers (Table 2). Chi-square analysis of genotype and allele distribution is in Table 2.
TABLE 2.
Allele and genotype frequencies Chi-square comparison for the soccer players and the controls.
| Genotype / allele / comparison type | Defenders | Attackers | Goalkeepers | Midfielders | All | Controls | ||
|---|---|---|---|---|---|---|---|---|
| n 31 | 15 | 14 | 39 | 99 | 107 | |||
| ACTN3 R577X | Allele n (%) | R | 35 (56.5) | 22 (73.3) | 14 (50.0) | 47 (60.2) | 118 (59.6) | 128 (59.8) |
| X | 27 (43.5) | 8 (26.7) | 14 (50.0) | 31 (39.7) | 80 (40.4) | 86 (40.2) | ||
| p | Compared to controls | 0.636 | 0.154 | 0.321 | 0.945 | 0.964 | - | |
| p | Compared to all | 0.661 | 0.150 | 0.335 | 0.920 | - | - | |
| Genotype n (%) | RR | 10 (32.3) | 7 (46.7) | 5 (35.7) | 12 (30.8) | 34 (34.3) | 36 (33.6) | |
| RX | 15 (48.4) | 8 (53.3) | 4 (28.6) | 23 (59.0) | 50 (50.5) | 56 (52.3) | ||
| XX | 6 (19.4) | 0 (0) | 5 (35.7) | 4 (10.3) | 15 (15.2) | 15 (14.0) | ||
| p | Compared to controls | 0.765 | 0.254 | 0.840 | 0.735 | 0.958 | - | |
| p | Compared to all | 0.857 | 0.241 | 0.124 | 0.615 | - | - | |
| ACE I/D | Allele n (%) | I | 35 (56.5) | 17 (56.7) | 13 (46.4) | 39 (50.0) | 104 (52.5) | |
| D | 27 (43.5) | 13 (43.3) | 15 (53.6) | 39 (50.0) | 94 (47.5) | |||
| p | Compared to controls | |||||||
| p | Compared to all | 0.589 | 0.672 | 0.546 | 0.705 | - | ||
| Genotype n (%) | II | 8 (25.8) | 4 (26.7) | 2 (14.3) | 10 (25.6) | 24 (24.2) | ||
| ID | 19 (61.3) | 9 (60.0) | 9 (64.3) | 19 (48.7) | 56 (56.6) | |||
| DD | 4 (12.9) | 2 (13.3) | 3 (21.4) | 10 (25.6) | 19 (19.2) | |||
| p | Compared to controls | |||||||
| p | Compared to all | 0.725 | 0.860 | 0.709 | 0.640 | - | ||
| NOS3 Glu298Asp | Allele n (%) | Glu | 51 (82.3) | 24 (80.0) | 22 (78.6) | 54 (69.2) | 151 (76.3) | 146 (68.2) |
| Asp | 11 (17.7) | 6 (20.0) | 6 (21.4) | 24 (30.8) | 47 (23.7) | 68 (31.8) | ||
| p | Compared to controls | 0.031* | 0.189 | 0.264 | 0.870 | 0.069 | - | |
| p | Compared to all | 0.322 | 0.652 | 0.787 | 0.229 | - | - | |
| Genotype n (%) | Glu/Glu | 21 (67.7) | 9 (60.0) | 8 (57.1) | 18 (46.2) | 56 (56.6) | 48 (44.9) | |
| Glu/Asp | 9 (29.0) | 6 (40.0) | 6 (42.9) | 18 (46.2) | 39 (39.4) | 50 (46.7) | ||
| Asp/Asp | 1 (3.2) | 0 (0) | 0 (0) | 3 (7.7) | 4 (4.0) | 9 (8.4) | ||
| p | Compared to controls | 0.075 | 0.361 | 0.445 | 0.985 | 0.166 | - | |
| p | Compared to all | 0.542 | 0.728 | 0.740 | 0.447 | - | - | |
| AMPD1 34C/T | Allele n (%) | C | 52 (83.9) | 26 (86.7) | 25 (89.3) | 69 (88.5) | 172 (86.9) | 179 (83.6) |
| T | 10 (16.1) | 4 (13.3) | 3 (10.7) | 9 (11.5) | 26 (13.1) | 35 (16.4) | ||
| p | Compared to controls | 0.966 | 0.672 | 0.440 | 0.309 | 0.357 | - | |
| p | Compared to all | 0.551 | 0.976 | 0.720 | 0.720 | - | - | |
| Genotype n (%) | C/C | 21 (67.7) | 11 (73.3) | 11 (78.6) | 30 (76.9) | 73 (73.7) | 76 (71.0) | |
| C/T | 10 (32.3) | 4 (26.7) | 3 (21.4) | 9 (23.1) | 26 (26.3) | 27 (25.2) | ||
| T/T | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0.0) | 4 (3.7) | ||
| p | Compared to controls | 0.441 | 0.748 | 0.707 | 0.439 | 0.152 | - | |
| p | Compared to all | 0.515 | 0.974 | 0,698 | 0.699 | - | - | |
| UCP2 Vla55Val | Allele n (%) | Ala | 38 (61.3) | 20 (66.7) | 13 (46.4) | 41 (52.6) | 112 (56.6) | 126 (58.9) |
| Val | 24 (38.7) | 10 (33.3) | 15 (53.6) | 37 (47.4) | 86 (43.4) | 88 (41.1) | ||
| p | Compared to controls | 0.733 | 0.415 | 0.210 | 0.335 | 0.635 | - | |
| p | Compared to all | 0.511 | 0.296 | 0.313 | 0.547 | - | - | |
| Genotype n (%) | Ala/Ala | 10 (32.3) | 6 (40.0) | 4 (28.6) | 9 (23.1) | 29 (23.3) | 37 (34.6) | |
| Ala/Val | 18 (58.1) | 8 (53.3) | 5 (35.7) | 23 (59.0) | 54 (54.5) | 52 (48.6) | ||
| Val/Val | 3 (9.7) | 1 (6.7) | 5 (35.7) | 7 (17.9) | 16 (16.2) | 18 (16.8) | ||
| p | Compared to controls | 0.530 | 0.594 | 0.235 | 0.402 | 0.665 | - | |
| p | Compared to all | 0.670 | 0.528 | 0.187 | 0.762 | - | - | |
| BDKRB2 +9/-9 | Allele n (%) | + 9 | 32 (51.6) | 15 (50.0) | 11 (39.3) | 36 (46.2) | 94 (47.5) | |
| -9 | 30 (48.4) | 15 (50.0) | 17 (60.7) | 42 (53.8) | 104 (52.5) | |||
| p | Compared to controls | |||||||
| p | Compared to all | 0.569 | 0.796 | 0.416 | 0.843 | - | ||
| Genotype n (%) | + 9/+9 | 9 (29.0) | 3 (20.0) | 1 (7.1) | 10 (25.6) | 23 (23.2) | ||
| +9/-9 | 14 (45.2) | 9 (60.0) | 9 (64.3) | 16 (41.0) | 48 (48.5) | |||
| -9/-9 | 8 (25.8) | 3 (20.0) | 4 (28.6) | 13 (33.3) | 28 (28.3) | |||
| p | Compared to controls | |||||||
| p | Compared to all | 0.807 | 0.693 | 0.350 | 0.725 | - | ||
| IL-1RN (VNTR 86-bp) | Allele (%) | IL1RN*1 | 39 (62.9) | 21 (70,0) | 23 (82.1) | 56 (71.8) | ||
| IL1RN*2 | 23 (37.1) | 9 (30,0) | 5 (17.9) | 22 (28.2) | ||||
| p | Compared to controls | |||||||
| p | Compared to all | 0.280 | 0.982 | 0.189 | 0.794 | |||
| Genotype (%) | IL1RN*1/ IL1RN*1 | 11 (35.5) | 8 (53,3) | 9 (64.3) | 21 (53.8) | |||
| IL1RN*1/ IL1RN*2 | 17 (54.8) | 5 (33.3) | 5 (35.7) | 14 (35.9) | ||||
| IL1RN*2/ IL1RN*2 | 3 (9.7) | 2 (13.3) | 0 (0) | 4 (10.3) | ||||
| p | Compared to controls | |||||||
| p | Compared to all | 0.374 | 0.782 | 0.267 | 0.836 | |||
p = the “p” values of the Chi-square test
statistically significant difference according to the Chi-square test.
Genotype-phenotype studies
The genotype differences were found in ACTN3 gene between quadriceps strength at 60°/s (F2, 156 = 4.8, p = 0.009, µ2 = 0.09), 180°/s (F2, 156 = 3.7, p = 0.026, µ2 = 0.16) and 300°/s (F2, 146 = 7.04, p = 0.001, µ2 = 0.08) in whole group, where XX genotypes resulted in lower quadriceps strength than RX heterozygotes and RR homozygotes whereas RR homozygotes has higher values than other genotypes (Figure 2). The ACTN3 genotypes differ also among hamstring strength at 60°/s (F2, 156 = 3.2, p = 0.042, µ2 = 0.04) and 300°/s (F2, 147 = 4.1, p < 0.017, µ2 = 0.05) in whole group, where XX genotype resulted in lower quadriceps strength than RX heterozygotes and RR homozygotes and RR homozygotes ( Figure 1).
FIG. 2.
Quadriceps and hamstring strength for AMPD1 C34T genotypes at high contraction speed.
*Significantly lower than other genotypes in the playing position. ** Significantly lower than different genotypes regardless of playing position. Significance is according to ANOVA and HSD test.
Further differences were found for ACTN3 genotypes and playing position interaction for quadriceps strength at speed of 60°/s (F3, 151 = 3.2, p = 0.025, µ2 = 0.06), speed of 180°/s (F3, 151 = 5.05, p = 0.002, µ2 = 0.09) and 300°/s (F3, 141 = 3.2, p = 0.024, µ2 = 0.06), where post hoc test showed that RR genotype in defenders position had higher quadriceps strength than other genotype groups in each tested speed and XX genotype in defenders had lower quadriceps strength than other genotype groups in each tested speed (Figure 1). No difference among genotypes has been observed in midfielders and for the attackers.
The differences in ACTN3 genotypes and playing position interaction were found for hamstring strength at speed of 60°/s (F3, 151 = 2.4, p = 0.05, µ2 = 0.05), speed of 180°/s (F3, 151 = 2.9, p = 0.034, µ2 = 0.06) and 300°/s (F3, 142 = 8.2, p = 0.047, µ2 = 0.06), showing that XX genotype in defenders had lower hamstring strength than other genotype groups in each tested speed and XX genotype had lower hamstring strength than other genotype groups in midfielders at 300°/s speed (Figure 1).
The ANOVA showed differences in AMPD1 genotypes for hamstrings (F1, 176 = 13.9, p < 0.001, µ2 = 0.073) and quadriceps (F1, 176 = 4.99, p = 0.027, µ2 = 0.027) at 300°/s in whole cohort, where CT genotype resulted in lower relative strength that CC genotype. The differences in AMPD1 by playing positions were found for hamstrings relative strength (F3, 170 = 3.2, p = 0.025, µ2 = 0.0754) and quadriceps relative strength (F3, 170 = 6.14, p = 0.014, µ2 = 0.034) at 300°/s, where CT heterozygotes showed lower relative hamstring strength in attackers, defenders and midfielders and lower relative quadriceps strength in attackers than CC homozygotes (Figure 2).
The differences in NOS3 genotypes for quadriceps absolute strength were found at speeds 60°/s (F1, 175 = 8.85, p = 0.003, µ2 = 0.048) and 180°/s (F1, 175 = 4.93, p < 0.027, µ2 = 0.027) in whole cohort, where Glu/Glu homozygotes showed higher strength than Glu/Asp heterozygotes (Figure 3). The differences in NOS3 genotypes by playing positions were found for quadriceps strength at speeds 60°/s (F1, 169 = 8.32, p = 0.004, µ2 = 0.046), 180°/s (F1, 169 = 5.26, p = 0.023, µ2 = 0.030), where Glu/Glu homozygotes showed higher strength in attackers, defenders and goalkeepers than Glu/Asp heterozygotes (Figure 3).
FIG. 3.
Quadriceps strength for NOS3 Glu298Asp genotypes and speeds of contraction in soccer player positions.
*Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.
The differences in IL1RN genotypes and playing position were found for hamstrings absolute strength at speeds 60°/s (F1, 167 = 6.9, p = 0.009, µ2 = 0.040), 180°/s (F1, 167 = 7.06, p < 0.009, µ2 = 0.041) and 300°/s (F1, 167 = 4.83, p < 0.029, µ2 = 0.029), where IL1RN*2 allele carriers (IL1RN*1/IL1RN*2+IL1RN *2/IL1RN*2) resulted in higher strength than IL1RN*1/IL1RN*1 homozygotes in attackers and goalkeepers (Figure 4). The differences in IL1RN genotypes in context of playing position have been found for quadriceps strength at 300°/s (F1, 158 = 4.8, p = 0.029, µ2 = 0.029), where IL1RN*2 allele carriers resulted in higher strength than IL1RN*1/IL1RN*1 in attackers and defenders (Figure 4).
FIG. 4.
Quadriceps and hamstring strength for IL1RN genotypes and speeds of contraction in soccer player positions.
*Significantly higher than other genotypes in the playing position according to ANOVA and HSD test.
We found no differences between tested phenotype traits in our soccer players concerning their playing position and genotypes for ACE (I/D, rs1799752), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761).
Polygenic study
The TGSsig included four genotypes (IL1RN, AMPD1 C34T, ACTN3 R577X, and NOS3 Glu298Asp) based on ANOVA results. Those TGSsig genotypes correlated with jump height in countermovement jump, squat jump, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s by r = 0.19, 0.20, 0.25, 0.20, and 0.19; respectively. Further linear-regression model of TGS including countermovement jump height, squat jump height, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s can explain 19% of this phenotype variance (R2 = 0.19, p = 0.009, Table 3).
TABLE 3.
The multiple backward regression for correlated phenotypes in all analyzed genes (TGS) and four significant genotypes (TGSsig).
| Phenotypes | b | SE | t | p | |
|---|---|---|---|---|---|
|
Jump height: countermovement jump squat jump Relative strength: quadriceps 60°/s and 300°/s hamstring strength at 300°/s |
Whole model | 2.25 | 0.31 | 10.02 | 0.005 |
| ACE (I/D) | 0,15 | 0.14 | 2.21 | 0.030 | |
| BDKRB2 (9/+9) | 0,22 | 0.18 | 2.54 | 0.013 | |
| NOS3 (Glu298Asp) | 0,38 | 0.14 | 4.20 | 0.001 | |
| IIL1RN (VNTR86-bp) | 0,24 | 0.16 | 2.61 | 0.011 | |
| AMPD1 (C34T) | 0,18 | 0.13 | 1.60 | 0.112 | |
| UCP2 (Ala55Val) | 0,19 | 0.16 | 2.32 | 0.023 | |
| ACTN3 (R577X) | 0,12 | 0.15 | 1.62 | 0.109 | |
| TGS * | -0,02 | 0.28 | -2.07 | 0.042 | |
|
Jump height: countermovement jump squat jump Relative strength: quadriceps 60°/s and 300°/s hamstring strength at 300°/s |
Whole model | 2,50 | 0,20 | 12,68 | < 0,001 |
| NOS3 (Glu298Asp) | 0,32 | 0,10 | 3,37 | < 0,001 | |
| IIL1RN (VNTR86-bp) | 0,16 | 0,09 | 1,76 | 0,083 | |
| AMPD1 (C34T) | 0,14 | 0,11 | 1,27 | 0,209 | |
| ACTN3 (R577X) | 0,09 | 0,08 | 1,09 | 0,277 | |
| TGSsig ** | -0,01 | 0,00 | -1,17 | 0,246 |
SE = standard error
explained phenotype variance R2 = 0.26, p = 0.005
explained phenotype variance R2 = 0.19, p = 0.009.
The TGS of all seven analyzed genotypes correlated with jump height in countermovement jump, squat jump, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s by r = 0.30, 0.24, 0.24, 0.27, and 0.30; respectively. Further linearregression model of TGS including countermovement jump height, squat jump height, relative quadriceps strength at 60°/s, 300°/s, and hamstring strength at 300°/s can explain 26% of this phenotype variance (R2 = 0.26, p = 0.005, Table 3).
DISCUSSION
Soccer belongs to the sport where speed is one of the main factors defining the difference between an excellent and an average athlete. Under this assumption, monitoring the lower extremities’ maximum strength on an isokinetic dynamometer is a non-invasive and indirect way to determine a predictor of speed capability [43, 44]. Our findings confirm the genetic connection to power-speed performance in soccer players’ positions in four out of seven previously reported gene polymorphisms [45], where ACTN3 had the most evident influence, including the phenotypes of both hamstring and quadriceps strength at all three speeds of contractions. Moreover, our results confirm the previous finding that TGS is associated with professional soccer players [32] and can predict the jump performance [46], where we are adding the TGS link to the muscle strength at different speeds of contractions (regardless of players´ position). An interesting result was that our TGS score of seven selected genotypes had more robust model prediction than TGSsig, including four genotypes. This confirms the major idea of TGS calculation that optimal genotypes profile for certain sport-related phenotypes requires multiple polymorphisms combinations, which are-related phenotypes that require multiple polymorphisms combinations related to different phenotype traits [46].
According to previous studies [7], our results confirm that the ACTN3 RR genotype is associated with speed, power, and strength in elite athletes. With other conditioning assumptions, this genotype can be one of the player’s premises [47], especially the in defenders. Conversely, the ACTN3 XX genotype seems to be related to a less pronounced phenotype in speed, power, and strength predispositions, which we observed in midfielders (Figures 1 and 2). Moreover, the ACTN3 XX genotype is possibly disadvantageous for attackers who did not contain any elite athlete in our cohort. This result corresponds to the link between the ACTN3 gene and muscle fiber type II, where the mutated X allele, especially of XX genotype, is less frequent in sprint and power athletes [48–50]. The physiological effect of the ACTN3 X allele leading to missing protein on the structural properties of the sarcomere is described elsewhere [48, 51]. ACTN3 gene coding alpha-actinin-3 protein belongs to groups of α-actinin isoforms, which are one of the main components of Z-line in muscle fiber [52], these form dimers that cross-link actin filaments. Expression of the ACTN3 gene is restricted only to type 2 fibers; thus, muscle fibers containing α-actinin-3 can achieve higher absorption and transfer of force potential in Z-lines during rapid contractions [53]. The main difference in playing position is the distance cover requirements in the soccer match, where midfielders track greater distance than attackers and defenders [54, 55]. Specifically, the central midfielders spend less time in maximum sprints [54]. On the other hand, there is also a record that midfielders have the highest number of acceleration and deceleration activities in the most physically demanding period (10 min) over a game [56].
Our results also show a connection between IL1RN*2 allele carriers and the speed, power, and strength hamstrings in attackers and goalkeepers and quadriceps strength in attackers and defenders; these carriers achieve increased strength levels. Thus IL1RN*2 allele carriers probably relate more to the speed predispositions, which is typical for attackers sprinting or fast goalkeeper reactions. In the past, the VNTR polymorphism in the IL1RN gene was associated with athlete status; the IL1RN*2 allele frequency was increased in professional athletes compared to amateur athletes with training times less than 10 hours a week [57]. Cauci et al. (2010) [57] also suggest that the IL1RN*2 alleles may favor adaptation to high-intensity exercise. Unfortunately, a comparison of our cohort soccer players’ allele/genotype frequencies with controls was not possible due to the unavailability of genotyping for this polymorphism in the control group.
Our study also indicates a connection between NOS3 Glu298Asp polymorphism and the measured parameters of lower limb strength/ power. NOS3 Glu/Glu homozygotes showed a higher level of strength in the attackers, defenders, and goalkeepers than Glu/Asp heterozygotes. This polymorphism’s possible effect on sports performance is related to the differential expression of endothelial NO synthase and the production of NO [58]. Our findings are consistent with [59] higher frequencies of the Glu298 allele in speed-strength-trained athletes than controls [59].
Finally, AMPD1 CT heterozygotes resulted in lower relative strength than CC homozygotes, while rare TT homozygotes were completely missing in our cohort. Nucleotide change C to T at position 34 in exon 2 (34C/T) leads to a nonsense codon mutation (Gln12X) prematurely terminating translation associated with AMP deaminase enzyme deficiency. Several studies consistently showed lower T allele frequencies in athletes compared to controls [60, 61].
No relationship has been found between tested strength/power parameters and genotypes for ACE (I/D, rs1799752), UCP2 (Ala55Val, rs660339), BDKRB2 (+9/-9, rs5810761); therefore, we suggest no significant contribution of these genetic variants on power and strength of lower limbs in our group soccer players. These findings are not exceptional as there is an inconsistency between genetic influence and speed/power performance in the literature for all mentioned polymorphisms [62–64].
Many studies evaluate the effects of genetic variants on elite (or sub-elite) soccer status [28, 65] or different traits that might be advantageous for soccer performance, including speed and power [66], endurance [67], or injury prevention [68]. For a comprehensive overview, current systematic reviews of McAuley et al. (2020) [7] or Sarmento et al. (2020) [69] suggest several gene variants, which can be beneficial for soccer and specifically for playing position in soccer as our findings exhibit. Nevertheless, sports scientists should keep in mind several things when interpreting the presented results, especially the noncoding biological variability, which continues to be uncovered in the human genome (e.g., epigenetic modifications, microRNAs, etc.). These other types of variability may contribute significantly to differences in athletic performance [70].
CONCLUSIONS
The strength and power measures are higher in elite soccer attackers and defenders, where some genetic markers can support these findings. Specifically, the ACTN3 RR and NOS3 Glu/Glu homozygotes and IL1RN*2 allele carriers have higher strength and power, and thus they seem to be pre-disposed to those attacker or defender playing positions. The midfielders have lower strength and power conditions than other players without relation to “strength and power genes.” The total genetic score regression explained 26% of the jump performance variance and isokinetic strength regardless of playing position.
Funding
Charles University, project GA UK No 180217, UNCE/HUM/032 and Czech science foundation no GA19-12150S
Acknowledgement
The study was supported by the Charles University, project GA UK No 180217, UNCE/HUM/032 and Czech science foundation no GA19-12150S.
Authors’ contributions
All authors met the authorship criteria for this journal and each author made a significant contribution to the final version of this paper.
SUPPLEMENTARY MATERIAL
TABLE S1.
The characteristic of the subjects
| All soccer players: | 99 |
|---|---|
| – Goalkeepers | 14 |
| – Defenders | 31 |
| – Midfielders | 39 |
| – Attackers | 15 |
| Age (y) | 25.4 ± 4.51 |
| Height (cm) | 181.4 ± 6.11 |
| Weight (kg) | 77.4 ± 7.22 |
TABLE S2.
Quantity of the components used for the PCR
| Genotype | DNA (μl) | DNA polymerase (μl) | Attackers primer/reverse primer (μl) | Buffer (μl) | dNTP (μl) | MgCl2 (μl) | Distilled H2O (μl) | Betain (μl) |
|---|---|---|---|---|---|---|---|---|
| ACE (I/D) | 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
| ACTN3 (R577X) | 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
| BDKRB2 (9/+9) | 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
| NOS3 (Glu298Asp) | 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
| AMPD1 (Gln12X) | 2 | Taq(5U/μl) 0,9 | 0,8 | 10xTaq Buffer with KCl 2,0 | 1,5 | 25mM MgCl21,6 | 6,4 | 4 |
| UCP2 (Ala55Val) | 2 | Taq(5U/μl) 0,4 | F 0,8 R 3,2 | 10xTaq Buffer with KCl 2,0 | 6 | 25mM MgCl21,6 | / | 4 |
| IL1RN (VNTR 86-bp) | 2 | Phusion 0,2 | 1 | 5xGC Buffer 4 | 4 | Buffer included | 3,8 | 4 |
TABLE S3.
Forward/reverse primers and PCR conditions for the examined genotypes
| Genotype | Forward primer (5’–3’) | Reverse primer (5’–3’) | PCR reaction conditions | ||
|---|---|---|---|---|---|
| Denaturation | Annealing and cycles | Final extension | |||
| ACE (I/D) | CTGGAGAGCCACTCCCATCCTTTCT | GACGTGGCCATCACATTCGTCAGAT | 98°C 30 s 98°C 10 s | 63°C 30 s – 35 cycles 72°C 30 s | 72°C 5 min |
| ACTN3 (R577X) | CTGTTGCCTGTGGTAAGTGGG | TGGTCACAGTATGCAGGAGGG | 94°C 30 s | 70°C 1 min – 35 cycles | 72°C 10 min |
| BDKRB2 (9/+9) | TCCAGCTCTGGCTTCTGG | AGTCGCTCCCTGGTACTGC | 98°C 30 s 98°C 10 s | 68°C 30 s – 35 cycles 72°C 30 s | 72°C 5 min |
| NOS3 (Glu298Asp) | CATGAGGCTCAGCCCCAGAAC | AGTCAATCCCTTTGGTGCTCAC | 98°C 30 s 98°C 10 s | 62°C 30 s – 35 cycles 72°C 10 s | 72°C 5 min |
| AMPD1 (Gln12X) | CTTCATACAGCTGAAGAGACA | GAATCCAGAAAAGCCATGAGC | 95°C 30 s | 56,4°C 1 min 72°C 30 s – 45 cycles | 72°C 5 min |
| UCP2 (Ala55Val) | TGGGAGTCTTGATGGTGTCTAC | CACCGCGGTACTGGGCGCTG | 95°C 30 s | 61,2°C 50 s 72°C 30 s – 46 cycles | 72°C 5 min |
| IL1RN (VNTR 86-bp) | CTCAGCAACACTCCTAT | TCCTGGTCTGCAGGTAA | 98°C 30 s | 57°C 30 s 72°C 30 s – 35 cycles | 72°C 5 min |
FIG. S1.
Quadriceps and hamstring strength at different speeds in the soccer player group.
*Significantly lower than other playing position groups at a defined speed of contraction according to ANOVA and HSD test.
REFERENCES
- 1.Rampinini E, Bishop D, Marcora S, Bravo DF, Sassi R, Impellizzeri F. Validity of simple field tests as indicators of match-related physical performance in top-level professional soccer players. Int J Sports Med. 2007;28:228–235. doi: 10.1055/s-2006-924340. [DOI] [PubMed] [Google Scholar]
- 2.Gissis I, Papadopoulos C, Kalapotharakos VI, Sotiropoulos A, Komsis G, Manolopoulos E. Strength and speed characteristics of elite, subelite, and recreational young soccer players. Res Sports Med. 2006;14:205–214. doi: 10.1080/15438620600854769. [DOI] [PubMed] [Google Scholar]
- 3.Pietraszewski P, Gołaś A, Matusiński A, Mrzygłód S, Mostowik A, Maszczyk A. Muscle Activity Asymmetry of the Lower Limbs During Sprinting in Elite Soccer Players. J Hum Kinet. 2020;75:239–245. doi: 10.2478/hukin-2020-0049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Chen Y, Wang D, Yan P, Yan S, Chang Q, Cheng Z. Meta-analyses of the association between the PPARGC1A Gly482Ser polymorphism and athletic performance. Biol Sport. 2019;36:301–309. doi: 10.5114/biolsport.2019.88752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Vigne G, Gaudino C, Rogowski I, Alloatti G, Hautier C. Activity profile in elite Italian soccer team. Int J Sports Med. 2010;31:304–10. doi: 10.1055/s-0030-1248320. [DOI] [PubMed] [Google Scholar]
- 6.Oliva-Lozano JM, Gómez-Carmona CD, Pino-Ortega J, Moreno-Pérez V, Rodríguez-Pérez MA. Match and training high intensity activity-demands profile during a competitive mesocycle in youth elite soccer players. J Hum Kinet. 2020;75:195–205. doi: 10.2478/hukin-2020-0050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.McAuley AB, Hughes DC, Tsaprouni LG, Varley I, Suraci B, Roos TR, et al. Genetic association research in football: a systematic review. Eur J Sport Sci. 2020:1–52. doi: 10.1080/17461391.2020.1776401. [DOI] [PubMed] [Google Scholar]
- 8.Pickering C, Suraci B, Semenova EA, Boulygina EA, Kostryukova ES, Kulemin NA, et al. A Genome-Wide Association Study of Sprint Performance in Elite Youth Football Players. J Strength Cond Res. 2019;33:2344–2351. doi: 10.1519/JSC.0000000000003259. [DOI] [PubMed] [Google Scholar]
- 9.Coelho DB, Pimenta E, Rosse IC, Veneroso C, Becker LK, Carvalho MR, et al. The alpha-actinin-3 r577x polymorphism and physical performance in soccer players. J Sports Med Phys Fitness. 2016;56:241–8. [PubMed] [Google Scholar]
- 10.Guilherme JP, Bosnyák E, Semenova E, Szmodis M, Griff A, Móra Á, et al. The MCT1 gene Glu490Asp polymorphism (rs1049434) is associated with endurance athlete status, lower blood lactate accumulation and higher maximum oxygen uptake. Biol Sport. 2021;38:465–474. doi: 10.5114/biolsport.2021.101638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lewis MI, Fournier M, Wang H, Storer TW, Casaburi R, Kopple JD. Effect of endurance and/or strength training on muscle fiber size, oxidative capacity, and capillarity in hemodialysis patients. J Appl Physiol. 2015;119:865–871. doi: 10.1152/japplphysiol.01084.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hamada T, Sale DG, MacDougall JD, Tarnopolsky MA. Postactivation potentiation, fiber type, and twitch contraction time in human knee extensor muscles. J Appl Physiol. 2000;88:2131–2137. doi: 10.1152/jappl.2000.88.6.2131. [DOI] [PubMed] [Google Scholar]
- 13.Booysen MJ, West N, Constantinou D. P-85 The relationships of eccentric and concentric isokinetic strength with sprinting speed in male sub-elite footballers. Br J Sports Med. 2016;50:A79. [Google Scholar]
- 14.Cometti G, Maffiuletti N, Pousson M, Chatard J-C, Maffulli N. Isokinetic strength and anaerobic power of elite, subelite and amateur French soccer players. Int J Sports Med. 2001;22:45–51. doi: 10.1055/s-2001-11331. [DOI] [PubMed] [Google Scholar]
- 15.Cotte T, Chatard J. Isokinetic strength and sprint times in English premier league football players. Biol Sport. 2011;28:89–94. [Google Scholar]
- 16.Harper D, Jordan A, Kiely J. Relationships between eccentric and concentric knee strength capacities and maximal linear deceleration ability in male academy soccer players. J Strength Condit Res. 2021;35:465–472. doi: 10.1519/JSC.0000000000002739. [DOI] [PubMed] [Google Scholar]
- 17.Tourny-Chollet C, Leroy D, Léger H, Beuret-Blanquart F. Isokinetic knee muscle strength of soccer players according to their position. Isokinetics and exercise science. 2000;8:187–193. [Google Scholar]
- 18.Śliwowski R, Grygorowicz M, Hojszyk R, Jadczak Ł. The isokinetic strength profile of elite soccer players according to playing position. PLoS One. 2017;12:e0182177. doi: 10.1371/journal.pone.0182177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Stastny P, Lehnert M, Tufano JJ. Muscle Imbalances: Testing and Training Functional Eccentric Hamstring Strength in Athletic Populations. JoVE. 2018:e57508. doi: 10.3791/57508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Chaouachi A, Manzi V, Chaalali A, Wong DP, Chamari K, Castagna C. Determinants analysis of change-of-direction ability in elite soccer players. J Strength Condit Res. 2012;26:2667–2676. doi: 10.1519/JSC.0b013e318242f97a. [DOI] [PubMed] [Google Scholar]
- 21.Coratella G, Beato M, Schena F. Correlation between quadriceps and hamstrings inter-limb strength asymmetry with change of direction and sprint in U21 elite soccer-players. Hum Mov Sci. 2018;59:81–87. doi: 10.1016/j.humov.2018.03.016. [DOI] [PubMed] [Google Scholar]
- 22.Mallo J, Mena E, Nevado F, Paredes V. Physical demands of top-class soccer friendly matches in relation to a playing position using global positioning system technology. J Human Kinet. 2015;47:179–188. doi: 10.1515/hukin-2015-0073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Modric T, Versic S, Sekulic D, Liposek S. Analysis of the Association between Running Performance and Game Performance Indicators in Professional Soccer Players. Int J Environ Res Publ Health. 2019;16:4032. doi: 10.3390/ijerph16204032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Boone J, Vaeyens R, Steyaert A, Bossche LV, Bourgois J. Physical fitness of elite Belgian soccer players by player position. J Strength Condit Res. 2012;26:2051–2057. doi: 10.1519/JSC.0b013e318239f84f. [DOI] [PubMed] [Google Scholar]
- 25.Boraczyński M, Boraczyński T, Podstawski R, Wójcik Z, Gronek P. Relationships Between Measures of Functional and Isometric Lower Body Strength, Aerobic Capacity, Anaerobic Power, Sprint and Countermovement Jump Performance in Professional Soccer Players. J Human Kinet. 2020;75:161–175. doi: 10.2478/hukin-2020-0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Massidda M, Mendez-Villanueva A, Ginevičienė V, Proia P, Drozdovska SB, Dosenko V, et al. Association of Monocarboxylate Transporter-1 (MCT1) A1470T Polymorphism (rs1049434) with Forward Football Player Status. Int J Sports Med. 2018;39:1028–1034. doi: 10.1055/a-0634-6387. [DOI] [PubMed] [Google Scholar]
- 27.Petr M, Maciejewska-Skrendo A, Zajac A, Chycki J, Stastny P. Association of Elite Sports Status with Gene Variants of Peroxisome Proliferator Activated Receptors and Their Transcriptional Coactivator. Int J Mol Sci. 2020;21:162. doi: 10.3390/ijms21010162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Santiago C, Gonzalez-Freire M, Serratosa L, Morate FJ, Meyer T, Gomez-Gallego F, et al. ACTN3 genotype in professional soccer players. Br J Sports Med. 2008;42:71–73. doi: 10.1136/bjsm.2007.039172. [DOI] [PubMed] [Google Scholar]
- 29.Honarpour A, Mohseni M, Hajiagha SG, Irani S, Najmabadi H. Investigation of the relationship between a genetic polymorphism in ACTN3 and elite sport performance among iranian soccer players. Iranian Rehabilitation Journal. 2017;15:149–154. [Google Scholar]
- 30.Coelho DB, Pimenta EM, Rosse IC, de Castro BM, Becker LK, de Oliveira EC, et al. Evidence for a Role of ACTN3 R577X Polymorphism in Football Player’s Career Progression. Int J Sports Med. 2018;39:1088–1093. doi: 10.1055/a-0753-4973. [DOI] [PubMed] [Google Scholar]
- 31.Pimenta EM, Coelho DB, Veneroso CE, Barros Coelho EJ, Cruz IR, Morandi RF, et al. Effect of ACTN3 gene on strength and endurance in soccer players. J Strength Cond Res. 2013;27:3286–3292. doi: 10.1519/JSC.0b013e3182915e66. [DOI] [PubMed] [Google Scholar]
- 32.Egorova ES, Borisova AV, Mustafina LJ, Arkhipova AA, Gabbasov RT, Druzhevskaya AM, et al. The polygenic profile of Russian football players. J Sports Sci. 2014;32:1286–1293. doi: 10.1080/02640414.2014.898853. [DOI] [PubMed] [Google Scholar]
- 33.Proia P, Bianco A, Schiera G, Saladino P, Contro V, Caramazza G, et al. PPARalpha gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players. J Sports Med. 2014;5:273–278. doi: 10.2147/OAJSM.S68333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Gineviciene V, Jakaitiene A, Tubelis L, Kucinskas V. Variation in the ACE, PPARGC1A and PPARA genes in Lithuanian football players. Eur J Sport Sci. 2014;14(Suppl 1):S289–295. doi: 10.1080/17461391.2012.691117. [DOI] [PubMed] [Google Scholar]
- 35.Weyerstrass J, Stewart K, Wesselius A, Zeegers M. Nine genetic polymorphisms associated with power athlete status – A Meta-Analysis. J Sci Med Sport. 2018;21:213–220. doi: 10.1016/j.jsams.2017.06.012. [DOI] [PubMed] [Google Scholar]
- 36.Alvarez-Romero J, Voisin S, Eynon N, Hiam D. Mapping Robust Genetic Variants Associated with Exercise Responses. Int J Sports Med. 2020;42:3–18. doi: 10.1055/a-1198-5496. [DOI] [PubMed] [Google Scholar]
- 37.Wang G, Mikami E, Chiu LL, A DEP, Deason M, Fuku N, et al. Association analysis of ACE and ACTN3 in elite Caucasian and East Asian swimmers. Med Sci Sports Exerc. 2013;45:892–900. doi: 10.1249/MSS.0b013e31827c501f. [DOI] [PubMed] [Google Scholar]
- 38.Cieszczyk P, Kalinski M, Ostanek M, Jascaniene N, Krupecki K, Ficek K, et al. Variation in the HIF1A gene in elite rowers. J Strength Condit Res. 2012;26:3270–3274. doi: 10.1519/JSC.0b013e31824b876d. [DOI] [PubMed] [Google Scholar]
- 39.Sawczuk M, Timshina YI, Astratenkova IV, Maciejewska-Karłowska A, Leońska-Duniec A, Ficek K, et al. The -9 / 9 Polymorphism of the Bradykinin Receptor Beta 2 Gene and Athlete Status: A Study Involving Two European Cohorts: BIOONE. Hum Biol. 2013;85:741–755. doi: 10.3378/027.085.0511. [DOI] [PubMed] [Google Scholar]
- 40.Maciejewska A, Sawczuk M, Cieszczyk P, Mozhayskaya IA, Ahmetov II. The PPARGC1A gene Gly482Ser in Polish and Russian athletes. J Sports Sci. 2012;30:101–113. doi: 10.1080/02640414.2011.623709. [DOI] [PubMed] [Google Scholar]
- 41.Williams AG, Folland JP. Similarity of polygenic profiles limits the potential for elite human physical performance. J Physiol. 2008;586:113–121. doi: 10.1113/jphysiol.2007.141887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Larson-Hall J. A guide to doing statistics in second language research using SPSS and R. Routledge; 2015. [Google Scholar]
- 43.González-Ravé JM, Juárez D, Rubio-Arias JA, Clemente-Suarez VJ, Martinez-Valencia MA, Abian-Vicen J. Isokinetic leg strength and power in elite handball players. J Hum Kinet. 2014;41:227–233. doi: 10.2478/hukin-2014-0050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Cronin JB, Hansen KT. Strength and power predictors of sports speed. J Strength Cond Res. 2005;19:349–357. doi: 10.1519/14323.1. [DOI] [PubMed] [Google Scholar]
- 45.Maciejewska-Skrendo A, Sawczuk M, Cięszczyk P, Ahmetov II. Chapter Three – Genes and power athlete status. In: Barh D, Ahmetov II, editors. Sports, Exercise, and Nutritional Genomics. Academic Press; 2019. pp. 41–72. [Google Scholar]
- 46.Massidda M, Scorcu M, Calò CM. New genetic model for predicting phenotype traits in sports. Int J Sports Physiol Perform. 2014;9:554–560. doi: 10.1123/ijspp.2012-0339. [DOI] [PubMed] [Google Scholar]
- 47.Clos E, Pruna R, Lundblad M, Artells R, Maffulli N. ACTN3’s R577X Single Nucleotide Polymorphism Allele Distribution Differs Significantly in Professional Football Players according to Their Field Position. Med Princ Pract. 2020;29:514–519. doi: 10.1159/000509089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Yang N, MacArthur D, Gulbin J, Hahn A, Beggs A, Easteal S, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73:627–631. doi: 10.1086/377590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Papadimitriou ID, Lucia A, Pitsiladis YP, Pushkarev VP, Dyatlov DA, Orekhov EF, et al. ACTN3 R577X and ACE I/D gene variants influence performance in elite sprinters: a multi-cohort study. BMC Genom. 2016;17:285. doi: 10.1186/s12864-016-2462-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Norman B, Esbjornsson M, Rundqvist H, Osterlund T, von Walden F, Tesch PA. Strength, power, fiber types, and mRNA expression in trained men and women with different ACTN3 R577X genotypes. J Appl Physiol. 2009;106:959–965. doi: 10.1152/japplphysiol.91435.2008. [DOI] [PubMed] [Google Scholar]
- 51.North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet. 1999;1:353–354. doi: 10.1038/7675. [DOI] [PubMed] [Google Scholar]
- 52.Blanchard A, Ohanian V, Critchley D. The structure and function of α-actinin. J Muscle Res Cell Motil. 1989;10:280–289. doi: 10.1007/BF01758424. [DOI] [PubMed] [Google Scholar]
- 53.Mills M, Yang N, Weinberger R, Vander Woude DL, Beggs AH, Easteal S, et al. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet. 2001;10:1335–1346. doi: 10.1093/hmg/10.13.1335. [DOI] [PubMed] [Google Scholar]
- 54.Di Salvo V, Baron R, Tschan H, Montero FC, Bachl N, Pigozzi F. Performance characteristics according to playing position in elite soccer. Int J Sports Med. 2007;28:222–227. doi: 10.1055/s-2006-924294. [DOI] [PubMed] [Google Scholar]
- 55.Andrzejewski M, Chmura J, Pluta B, Konarski JM. Sprinting activities and distance covered by top level Europa league soccer players. International Journal of Sports Science & Coaching. 2015;10:39–50. [Google Scholar]
- 56.Martín-García A, Casamichana D, Díaz AG, Cos F, Gabbett TJ. Positional differences in the most demanding passages of play in football competition. J Sports Sci Med. 2018;17:563. [PMC free article] [PubMed] [Google Scholar]
- 57.Cauci S, Di Santolo M, Ryckman KK, Williams SM, Banfi G. Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status. BMC Med Genet. 2010;11:29. doi: 10.1186/1471-2350-11-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Dosenko VE, Zagoriy VY, Haytovich NV, Gordok OA, Moibenko AA. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Biochimica Polonica. 2006;53:299–302. [PubMed] [Google Scholar]
- 59.Sessa F, Chetta M, Petito A, Franzetti M, Bafunno V, Pisanelli D, et al. Gene polymorphisms and sport attitude in Italian athletes. Genetic testing and molecular biomarkers. 2011;15:285–290. doi: 10.1089/gtmb.2010.0179. [DOI] [PubMed] [Google Scholar]
- 60.Cieszczyk P, Eider J, Ostanek M, Leonska-Duniec A, Ficek K, Kotarska K, et al. Is the C34T polymorphism of the AMPD1 gene associated with athlete performance in rowing? Int J Sports Med. 2011;32:987–991. doi: 10.1055/s-0031-1283186. [DOI] [PubMed] [Google Scholar]
- 61.Fedotovskaya ON, Danilova AA, Akhmetov II. Effect of AMPD1 gene polymorphism on muscle activity in humans. Bull Exp Biol Med. 2013;154:489–491. doi: 10.1007/s10517-013-1984-9. [DOI] [PubMed] [Google Scholar]
- 62.Scott RA, Irving R, Irwin L, Morrison E, Charlton V, Austin K, et al. ACTN3 and ACE genotypes in elite Jamaican and US sprinters. Med Sci Sports Exerc. 2010;42:107–112. doi: 10.1249/MSS.0b013e3181ae2bc0. [DOI] [PubMed] [Google Scholar]
- 63.Eynon N, Hanson ED, Lucia A, Houweling PJ, Garton F, North KN, et al. Genes for elite power and sprint performance: ACTN3 leads the way. Sports Med. 2013;43:803–817. doi: 10.1007/s40279-013-0059-4. [DOI] [PubMed] [Google Scholar]
- 64.Eynon N, Meckel Y, Alves AJ, Nemet D, Eliakim A. Is there an interaction between BDKRB2− 9/+ 9 and GNB3 C825T polymorphisms and elite athletic performance? Scand J Med Sci Sports. 2011;21:e242–e6. doi: 10.1111/j.1600-0838.2010.01261.x. [DOI] [PubMed] [Google Scholar]
- 65.Eynon N, Ruiz JR, Yvert T, Santiago C, Gómez-Gallego F, Lucia A, et al. The C allele in NOS3 -786 T/C polymorphism is associated with elite soccer player’s status. Int J Sports Med. 2012;33:521–524. doi: 10.1055/s-0032-1306337. [DOI] [PubMed] [Google Scholar]
- 66.Massidda M, Corrias L, Ibba G, Scorcu M, Vona G, Calò CM. Genetic markers and explosive leg-muscle strength in elite Italian soccer players. J Sports Med Phys Fitness. 2012;52:328–234. [PubMed] [Google Scholar]
- 67.Dinç N, Yücel SB, Taneli F, Sayın MV. The effect of the MTHFR C677T mutation on athletic performance and the homocysteine level of soccer players and sedentary individuals. J Hum Kinet. 2016;51:61–69. doi: 10.1515/hukin-2015-0171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Lulinska-Kuklik E, Rahim M, Domanska-Senderowska D, Ficek K, Michalowska-Sawczyn M, Moska W, et al. Interactions between COL5A1 Gene and Risk of the Anterior Cruciate Ligament Rupture. J Hum Kinet. 2018;62:65–71. doi: 10.1515/hukin-2017-0177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Sarmento H, Marques A, Field A, Martins J, Gouveia É, Mondagrón L, et al. Genetic influence on football performance – a systematic review. Human Movement. 2020;21:1–17. [Google Scholar]
- 70.Posthumus M, Collins M. Genetics and sports. Karger Medical and Scientific Publishers; 2016. [Google Scholar]





